{"id":123363,"date":"2025-11-04T11:51:24","date_gmt":"2025-11-04T08:51:24","guid":{"rendered":"https:\/\/indexeconomic.com\/?p=123363"},"modified":"2025-11-04T11:51:24","modified_gmt":"2025-11-04T08:51:24","slug":"lilly-reports-third-quarter-2025-financial-results-highlights-rd-pipeline-momentum-and-raises-2025-guidance","status":"publish","type":"post","link":"https:\/\/indexeconomic.com\/?p=123363","title":{"rendered":"Lilly reports third-quarter 2025 financial results, highlights R&#038;D pipeline momentum and raises 2025 guidance"},"content":{"rendered":"<p style=\"text-align: left;\">\n<p style=\"text-align: left;\"><strong>\u00a0<\/strong><\/p>\n<ul style=\"text-align: left;\">\n<li><em>Revenue in Q3 2025 increased 54% to\u00a0$17.60 billion\u00a0driven by volume growth from Mounjaro and Zepbound<\/em>.<\/li>\n<li><em>Q3 2025<\/em>\u00a0\u00a0<em>\u00a0EPS increased by\u00a0$5.14\u00a0to\u00a0$6.21\u00a0on a reported basis and increased by\u00a0$5.84\u00a0to\u00a0$7.02\u00a0on a non-GAAP basis.<\/em><\/li>\n<li><em>Increased our 2025 full-year revenue guidance to be in the range of\u00a0$63.0 billion\u00a0to\u00a0$63.5 billion; reported EPS guidance raised to be in the range of\u00a0$21.80\u00a0to\u00a0$22.50\u00a0and non-GAAP EPS guidance raised to be in the range of\u00a0$23.00\u00a0to\u00a0$23.70.<\/em><\/li>\n<li><em>Pipeline progress included positive results in four Phase 3 trials of orforglipron, across type 2 diabetes and obesity, with plans to submit to global regulatory authorities by the end of the year for the treatment of obesity.<\/em><\/li>\n<li><em>Regulatory progress included\u00a0U.S.\u00a0FDA approval of Inluriyo (imlunestrant) for certain adults with advanced or metastatic breast cancer.<\/em><\/li>\n<li><em>Manufacturing progress included announcements of two new facilities in\u00a0Virginia\u00a0and\u00a0Texas, and the expansion of Lilly&#8217;s existing\u00a0Puerto Rico\u00a0site.<\/em><\/li>\n<\/ul>\n<p style=\"text-align: left;\">\n<p style=\"text-align: left;\">04<sup>th<\/sup>\u00a0 November 2025: Eli Lilly and Company\u00a0(NYSE: LLY) today announced its financial results for the third-quarter of 2025.<\/p>\n<p style=\"text-align: left;\">&#8220;Lilly delivered another strong quarter, with 54% revenue growth year-over-year driven by continued demand for our incretin portfolio,&#8221; said\u00a0David A. Ricks, Lilly chair and CEO. &#8220;We advanced orforglipron through four additional Phase 3 trials, enabling global obesity submissions by year-end, and we achieved\u00a0U.S.\u00a0FDA approval of Inluriyo (imlunestrant)\u2014marking key progress across our pipeline. We continue to increase manufacturing capacity, announcing new facilities in\u00a0Virginia\u00a0and\u00a0Texas\u00a0and an expansion of our site in\u00a0Puerto Rico.&#8221;<\/p>\n<p style=\"text-align: left;\">A discussion of the non-GAAP financial measures is included below under &#8220;Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited).&#8221;<\/p>\n<p style=\"text-align: left;\"><u><br \/>\n<\/u>In Q3 2025, worldwide revenue was\u00a0$17.60 billion, an increase of 54% compared with Q3 2024, driven by a 62% increase in volume, partially offset by a 10% decrease due to lower realized prices. Key Products<sup>1<\/sup>\u00a0revenue grew to\u00a0$11.98 billion\u00a0in Q3 2025, led by Mounjaro and Zepbound.<\/p>\n<p style=\"text-align: left;\">Revenue in the\u00a0U.S.\u00a0increased 45% to\u00a0$11.30 billion, driven by a 60% increase in volume, partially offset by a 15% decrease due to lower realized prices. Price was negatively impacted by a favorable one-time adjustment to estimates for rebates and discounts in Q3 2024. Excluding this base period effect,\u00a0U.S.\u00a0price declined by high single digits.<\/p>\n<p style=\"text-align: left;\">Revenue outside the\u00a0U.S.\u00a0increased 74% to\u00a0$6.30 billion, driven by a 66% increase in volume and to a lesser extent a 6% favorable impact on foreign exchange rates. The volume increase outside the\u00a0U.S.\u00a0was driven primarily by Mounjaro. Revenue included a\u00a0$200.0\u00a0million sales-based milestone payment for Jardiance and\u00a0$180.0 million\u00a0of revenue associated with the divestiture of the rights to Cialis in select markets outside of the\u00a0U.S.<\/p>\n<p style=\"text-align: left;\">Gross margin increased 57% to\u00a0$14.59 billion\u00a0in Q3 2025. Gross margin as a percent of revenue was 82.9%, an increase of 1.9 percentage points. The increase in gross margin percent was primarily driven by favorable product mix, partially offset by lower realized prices.<\/p>\n<p style=\"text-align: left;\">In Q3 2025, research and development expenses increased 27% to\u00a0$3.47 billion, or 19.7% of revenue, driven by continued investments in the company&#8217;s early and late-stage portfolio.<\/p>\n<p style=\"text-align: left;\">Marketing, selling and administrative expenses increased 31% to\u00a0$2.74 billion\u00a0in Q3 2025, primarily driven by promotional efforts supporting ongoing and future launches.<\/p>\n<p style=\"text-align: left;\">In Q3 2025, the company recognized acquired in-process research and development (IPR&amp;D) charges of\u00a0$655.7 million compared with\u00a0$2.83 billion\u00a0in Q3 2024. The Q3 2025 charges primarily related to the\u00a0acquisition of\u00a0SiteOne Therapeutics, Inc.\u00a0The Q3 2024 charges were primarily related to the acquisition of\u00a0Morphic Holding, Inc.<\/p>\n<p style=\"text-align: left;\">Asset impairment, restructuring and other special charges of\u00a0$364.9 million\u00a0in Q3 2025 were primarily related to a litigation charge, as well as acquisition and integration costs associated with the closing of our acquisition of\u00a0Verve Therapeutics, Inc.\u00a0In Q3 2024, there was a charge of\u00a0$81.6 million, that primarily related to impairment of an intangible asset associated with a molecule in development.<\/p>\n<p style=\"text-align: left;\">The effective tax rate was 22.8% in Q3 2025 compared with 38.9% in Q3 2024. The effective tax rates for Q3 2025 and Q3 2024 were both unfavorably impacted by non-deductible acquired IPR&amp;D charges, with a larger impact occurring in Q3 2024. Additionally, the effective tax rate for Q3 2025 was unfavorably impacted by\u00a0U.S.\u00a0tax law changes enacted during the quarter.<\/p>\n<p style=\"text-align: left;\">In Q3 2025, net income and earnings per share (EPS) were\u00a0$5.58\u00a0billion and\u00a0$6.21, respectively, compared with net income of\u00a0$970.3\u00a0million and EPS of\u00a0$1.07\u00a0in Q3 2024. EPS in Q3 2025 and Q3 2024 included acquired IPR&amp;D charges of\u00a0$0.71\u00a0and\u00a0$3.08, respectively.<\/p>\n<p style=\"text-align: left;\"><u><br \/>\n<\/u>On a non-GAAP basis, Q3 2025 gross margin increased 56% to\u00a0$14.71 billion. Gross margin as a percent of revenue was 83.6%, an increase of 1.4 percentage points. The increase in gross margin percent was primarily driven by favorable product mix, partially offset by lower realized prices.<\/p>\n<p style=\"text-align: left;\">The non-GAAP effective tax rate was 17.7% in Q3 2025 compared with 37.6% in Q3 2024. The effective tax rates for Q3 2025 and Q3 2024 were both unfavorably impacted by non-deductible acquired IPR&amp;D charges, with a larger impact occurring in Q3 2024.<\/p>\n<p style=\"text-align: left;\">On a non-GAAP basis, Q3 2025 net income and EPS were\u00a0$6.31 billion\u00a0and\u00a0$7.02, respectively, compared with net income of\u00a0$1.06\u00a0billion and EPS of\u00a0$1.18\u00a0in Q3 2024. Non-GAAP EPS in Q3 2025 and Q3 2024 included acquired IPR&amp;D charges of\u00a0$0.71\u00a0and\u00a0$3.08, respectively.<\/p>\n<p style=\"text-align: left;\">For further detail on non-GAAP measures, see the reconciliation below as well as the &#8220;Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)&#8221; table later in this press release.<\/p>\n<p style=\"text-align: left;\"><u>Mounjaro<br \/>\n<\/u>For Q3 2025, worldwide Mounjaro revenue increased 109% to\u00a0$6.52 billion.\u00a0U.S.\u00a0revenue was\u00a0$3.55 billion, an increase of 49%, reflecting strong demand, partially offset by lower realized prices. Revenue outside the\u00a0U.S.\u00a0increased to\u00a0$2.97 billion\u00a0compared with\u00a0$728.0 million\u00a0in Q3 2024, primarily driven by volume growth.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00a0 Revenue in Q3 2025 increased 54% to\u00a0$17.60 billion\u00a0driven by volume growth from Mounjaro and Zepbound. Q3 2025\u00a0\u00a0\u00a0EPS increased by\u00a0$5.14\u00a0to\u00a0$6.21\u00a0on a reported basis and increased by\u00a0$5.84\u00a0to\u00a0$7.02\u00a0on a non-GAAP basis. Increased our 2025 full-year revenue guidance to be in the range of\u00a0$63.0 billion\u00a0to\u00a0$63.5 billion; reported EPS guidance raised to be in the range of\u00a0$21.80\u00a0to\u00a0$22.50\u00a0and non-GAAP EPS &hellip;<\/p>\n","protected":false},"author":2,"featured_media":123364,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[439],"tags":[],"class_list":["post-123363","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-english-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lilly reports third-quarter 2025 financial results, highlights R&amp;D pipeline momentum and raises 2025 guidance - \u0635\u062d\u064a\u0641\u0629 \u0627\u0644\u0645\u0624\u0634\u0631 \u0627\u0644\u0625\u0642\u062a\u0635\u0627\u062f\u064a<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/indexeconomic.com\/?p=123363\" \/>\n<meta property=\"og:locale\" content=\"ar_AR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lilly reports third-quarter 2025 financial results, highlights R&amp;D pipeline momentum and raises 2025 guidance - \u0635\u062d\u064a\u0641\u0629 \u0627\u0644\u0645\u0624\u0634\u0631 \u0627\u0644\u0625\u0642\u062a\u0635\u0627\u062f\u064a\" \/>\n<meta property=\"og:description\" content=\"\u00a0 Revenue in Q3 2025 increased 54% to\u00a0$17.60 billion\u00a0driven by volume growth from Mounjaro and Zepbound. Q3 2025\u00a0\u00a0\u00a0EPS increased by\u00a0$5.14\u00a0to\u00a0$6.21\u00a0on a reported basis and increased by\u00a0$5.84\u00a0to\u00a0$7.02\u00a0on a non-GAAP basis. Increased our 2025 full-year revenue guidance to be in the range of\u00a0$63.0 billion\u00a0to\u00a0$63.5 billion; reported EPS guidance raised to be in the range of\u00a0$21.80\u00a0to\u00a0$22.50\u00a0and non-GAAP EPS &hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/indexeconomic.com\/?p=123363\" \/>\n<meta property=\"og:site_name\" content=\"\u0635\u062d\u064a\u0641\u0629 \u0627\u0644\u0645\u0624\u0634\u0631 \u0627\u0644\u0625\u0642\u062a\u0635\u0627\u062f\u064a\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-04T08:51:24+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/indexeconomic.com\/wp-content\/uploads\/2025\/11\/Lilly-logo.png\" \/>\n\t<meta property=\"og:image:width\" content=\"304\" \/>\n\t<meta property=\"og:image:height\" content=\"166\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"\u0639\u0628\u062f\u0647 \u0627\u0644\u0645\u0647\u062f\u064a\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u0639\u0628\u062f\u0647 \u0627\u0644\u0645\u0647\u062f\u064a\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 \u062f\u0642\u0627\u0626\u0642\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/indexeconomic.com\\\/?p=123363#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/indexeconomic.com\\\/?p=123363\"},\"author\":{\"name\":\"\u0639\u0628\u062f\u0647 \u0627\u0644\u0645\u0647\u062f\u064a\",\"@id\":\"https:\\\/\\\/indexeconomic.com\\\/#\\\/schema\\\/person\\\/ec72ed13059cd206a1153d37f4287a48\"},\"headline\":\"Lilly reports third-quarter 2025 financial results, highlights R&#038;D pipeline momentum and raises 2025 guidance\",\"datePublished\":\"2025-11-04T08:51:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/indexeconomic.com\\\/?p=123363\"},\"wordCount\":909,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/indexeconomic.com\\\/?p=123363#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/indexeconomic.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Lilly-logo.png\",\"articleSection\":[\"English News\"],\"inLanguage\":\"ar\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/indexeconomic.com\\\/?p=123363#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/indexeconomic.com\\\/?p=123363\",\"url\":\"https:\\\/\\\/indexeconomic.com\\\/?p=123363\",\"name\":\"Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance - \u0635\u062d\u064a\u0641\u0629 \u0627\u0644\u0645\u0624\u0634\u0631 \u0627\u0644\u0625\u0642\u062a\u0635\u0627\u062f\u064a\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/indexeconomic.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/indexeconomic.com\\\/?p=123363#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/indexeconomic.com\\\/?p=123363#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/indexeconomic.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Lilly-logo.png\",\"datePublished\":\"2025-11-04T08:51:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/indexeconomic.com\\\/#\\\/schema\\\/person\\\/ec72ed13059cd206a1153d37f4287a48\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/indexeconomic.com\\\/?p=123363#breadcrumb\"},\"inLanguage\":\"ar\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/indexeconomic.com\\\/?p=123363\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/indexeconomic.com\\\/?p=123363#primaryimage\",\"url\":\"https:\\\/\\\/indexeconomic.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Lilly-logo.png\",\"contentUrl\":\"https:\\\/\\\/indexeconomic.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Lilly-logo.png\",\"width\":304,\"height\":166},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/indexeconomic.com\\\/?p=123363#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u0627\u0644\u0631\u0626\u064a\u0633\u064a\u0629\",\"item\":\"https:\\\/\\\/indexeconomic.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lilly reports third-quarter 2025 financial results, highlights R&#038;D pipeline momentum and raises 2025 guidance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/indexeconomic.com\\\/#website\",\"url\":\"https:\\\/\\\/indexeconomic.com\\\/\",\"name\":\"\u0635\u062d\u064a\u0641\u0629 \u0627\u0644\u0645\u0624\u0634\u0631 \u0627\u0644\u0625\u0642\u062a\u0635\u0627\u062f\u064a\",\"description\":\"\u062f\u0642\u0629 \u0627\u0644\u062a\u062d\u0644\u064a\u0644\u0627\u062a\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/indexeconomic.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ar\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/indexeconomic.com\\\/#\\\/schema\\\/person\\\/ec72ed13059cd206a1153d37f4287a48\",\"name\":\"\u0639\u0628\u062f\u0647 \u0627\u0644\u0645\u0647\u062f\u064a\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/807eb9a4a275ddb2487fd1fb0a47fdf5ded144089bbefe69bd6293cd21b53b18?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/807eb9a4a275ddb2487fd1fb0a47fdf5ded144089bbefe69bd6293cd21b53b18?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/807eb9a4a275ddb2487fd1fb0a47fdf5ded144089bbefe69bd6293cd21b53b18?s=96&d=mm&r=g\",\"caption\":\"\u0639\u0628\u062f\u0647 \u0627\u0644\u0645\u0647\u062f\u064a\"},\"sameAs\":[\"http:\\\/\\\/www.indexeconomic.com\\\/\"],\"url\":\"https:\\\/\\\/indexeconomic.com\\\/?author=2\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance - \u0635\u062d\u064a\u0641\u0629 \u0627\u0644\u0645\u0624\u0634\u0631 \u0627\u0644\u0625\u0642\u062a\u0635\u0627\u062f\u064a","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/indexeconomic.com\/?p=123363","og_locale":"ar_AR","og_type":"article","og_title":"Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance - \u0635\u062d\u064a\u0641\u0629 \u0627\u0644\u0645\u0624\u0634\u0631 \u0627\u0644\u0625\u0642\u062a\u0635\u0627\u062f\u064a","og_description":"\u00a0 Revenue in Q3 2025 increased 54% to\u00a0$17.60 billion\u00a0driven by volume growth from Mounjaro and Zepbound. Q3 2025\u00a0\u00a0\u00a0EPS increased by\u00a0$5.14\u00a0to\u00a0$6.21\u00a0on a reported basis and increased by\u00a0$5.84\u00a0to\u00a0$7.02\u00a0on a non-GAAP basis. Increased our 2025 full-year revenue guidance to be in the range of\u00a0$63.0 billion\u00a0to\u00a0$63.5 billion; reported EPS guidance raised to be in the range of\u00a0$21.80\u00a0to\u00a0$22.50\u00a0and non-GAAP EPS &hellip;","og_url":"https:\/\/indexeconomic.com\/?p=123363","og_site_name":"\u0635\u062d\u064a\u0641\u0629 \u0627\u0644\u0645\u0624\u0634\u0631 \u0627\u0644\u0625\u0642\u062a\u0635\u0627\u062f\u064a","article_published_time":"2025-11-04T08:51:24+00:00","og_image":[{"width":304,"height":166,"url":"http:\/\/indexeconomic.com\/wp-content\/uploads\/2025\/11\/Lilly-logo.png","type":"image\/png"}],"author":"\u0639\u0628\u062f\u0647 \u0627\u0644\u0645\u0647\u062f\u064a","twitter_card":"summary_large_image","twitter_misc":{"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629":"\u0639\u0628\u062f\u0647 \u0627\u0644\u0645\u0647\u062f\u064a","\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631":"8 \u062f\u0642\u0627\u0626\u0642"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/indexeconomic.com\/?p=123363#article","isPartOf":{"@id":"https:\/\/indexeconomic.com\/?p=123363"},"author":{"name":"\u0639\u0628\u062f\u0647 \u0627\u0644\u0645\u0647\u062f\u064a","@id":"https:\/\/indexeconomic.com\/#\/schema\/person\/ec72ed13059cd206a1153d37f4287a48"},"headline":"Lilly reports third-quarter 2025 financial results, highlights R&#038;D pipeline momentum and raises 2025 guidance","datePublished":"2025-11-04T08:51:24+00:00","mainEntityOfPage":{"@id":"https:\/\/indexeconomic.com\/?p=123363"},"wordCount":909,"commentCount":0,"image":{"@id":"https:\/\/indexeconomic.com\/?p=123363#primaryimage"},"thumbnailUrl":"https:\/\/indexeconomic.com\/wp-content\/uploads\/2025\/11\/Lilly-logo.png","articleSection":["English News"],"inLanguage":"ar","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/indexeconomic.com\/?p=123363#respond"]}]},{"@type":"WebPage","@id":"https:\/\/indexeconomic.com\/?p=123363","url":"https:\/\/indexeconomic.com\/?p=123363","name":"Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance - \u0635\u062d\u064a\u0641\u0629 \u0627\u0644\u0645\u0624\u0634\u0631 \u0627\u0644\u0625\u0642\u062a\u0635\u0627\u062f\u064a","isPartOf":{"@id":"https:\/\/indexeconomic.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/indexeconomic.com\/?p=123363#primaryimage"},"image":{"@id":"https:\/\/indexeconomic.com\/?p=123363#primaryimage"},"thumbnailUrl":"https:\/\/indexeconomic.com\/wp-content\/uploads\/2025\/11\/Lilly-logo.png","datePublished":"2025-11-04T08:51:24+00:00","author":{"@id":"https:\/\/indexeconomic.com\/#\/schema\/person\/ec72ed13059cd206a1153d37f4287a48"},"breadcrumb":{"@id":"https:\/\/indexeconomic.com\/?p=123363#breadcrumb"},"inLanguage":"ar","potentialAction":[{"@type":"ReadAction","target":["https:\/\/indexeconomic.com\/?p=123363"]}]},{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/indexeconomic.com\/?p=123363#primaryimage","url":"https:\/\/indexeconomic.com\/wp-content\/uploads\/2025\/11\/Lilly-logo.png","contentUrl":"https:\/\/indexeconomic.com\/wp-content\/uploads\/2025\/11\/Lilly-logo.png","width":304,"height":166},{"@type":"BreadcrumbList","@id":"https:\/\/indexeconomic.com\/?p=123363#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u0627\u0644\u0631\u0626\u064a\u0633\u064a\u0629","item":"https:\/\/indexeconomic.com\/"},{"@type":"ListItem","position":2,"name":"Lilly reports third-quarter 2025 financial results, highlights R&#038;D pipeline momentum and raises 2025 guidance"}]},{"@type":"WebSite","@id":"https:\/\/indexeconomic.com\/#website","url":"https:\/\/indexeconomic.com\/","name":"\u0635\u062d\u064a\u0641\u0629 \u0627\u0644\u0645\u0624\u0634\u0631 \u0627\u0644\u0625\u0642\u062a\u0635\u0627\u062f\u064a","description":"\u062f\u0642\u0629 \u0627\u0644\u062a\u062d\u0644\u064a\u0644\u0627\u062a","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/indexeconomic.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ar"},{"@type":"Person","@id":"https:\/\/indexeconomic.com\/#\/schema\/person\/ec72ed13059cd206a1153d37f4287a48","name":"\u0639\u0628\u062f\u0647 \u0627\u0644\u0645\u0647\u062f\u064a","image":{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/secure.gravatar.com\/avatar\/807eb9a4a275ddb2487fd1fb0a47fdf5ded144089bbefe69bd6293cd21b53b18?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/807eb9a4a275ddb2487fd1fb0a47fdf5ded144089bbefe69bd6293cd21b53b18?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/807eb9a4a275ddb2487fd1fb0a47fdf5ded144089bbefe69bd6293cd21b53b18?s=96&d=mm&r=g","caption":"\u0639\u0628\u062f\u0647 \u0627\u0644\u0645\u0647\u062f\u064a"},"sameAs":["http:\/\/www.indexeconomic.com\/"],"url":"https:\/\/indexeconomic.com\/?author=2"}]}},"_links":{"self":[{"href":"https:\/\/indexeconomic.com\/index.php?rest_route=\/wp\/v2\/posts\/123363","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/indexeconomic.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/indexeconomic.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/indexeconomic.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/indexeconomic.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=123363"}],"version-history":[{"count":1,"href":"https:\/\/indexeconomic.com\/index.php?rest_route=\/wp\/v2\/posts\/123363\/revisions"}],"predecessor-version":[{"id":123365,"href":"https:\/\/indexeconomic.com\/index.php?rest_route=\/wp\/v2\/posts\/123363\/revisions\/123365"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/indexeconomic.com\/index.php?rest_route=\/wp\/v2\/media\/123364"}],"wp:attachment":[{"href":"https:\/\/indexeconomic.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=123363"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/indexeconomic.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=123363"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/indexeconomic.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=123363"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}